Uppsala universitet,Endokrinkirurgi,Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
Hammar, Niklas (författare)
Department of Clinical Science, Intervention and Technology (CLINTEC),Inst Environm Med, Epidemiol Unit, Stockholm, Sweden.; Global Med Affairs AstraZeneca, Med Evidence & Observat Res, Molndal, Sweden.,Department of Clinical Science, Intervention and Technology (CLINTEC),Department of Clinical Science, Intervention and Technology (CLINTEC)
Adolfsson, Jan (författare)
Department of Clinical Science, Intervention and Technology (CLINTEC),Karolinska Inst, CLINTEC Dept, Stockholm, Sweden,Department of Clinical Science, Intervention and Technology (CLINTEC),Department of Clinical Science, Intervention and Technology (CLINTEC)
To evaluate whether drugs for metabolic conditions influence prostate cancer‐specific mortality in men starting gonadotrophin‐releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists.Patients and MethodsWe selected all men receiving GnRH agonists as primary treatment in the Prostate Cancer data Base Sweden (PCBaSe) (n = 9267). Use of drugs for metabolic conditions (i.e. anti‐diabetes, anti‐dyslipidaemia, and antihypertension) in relation to all‐cause, cardiovascular disease (CVD), and prostate cancer‐specific death were studied using multivariate Cox proportional hazard and Fine and Gray competing regression models.ResultsIn all, 6322 (68%) men used at least one drug for a metabolic condition at GnRH agonist initiation: 46% on antihypertensive drugs only, 32% on drugs for dyslipidaemia and hypertension, and ~10% on drugs for more than two metabolic conditions. Cox models indicated a weak increased risk of prostate cancer death in men who were on drugs for hypertension only (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03–1.23) or drugs for hyperglycaemia (HR 1.19, 95% CI 1.06–1.35) at GnRH agonist initiation. However, upon taking into account competing risk from CVD death, none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death.ConclusionWe did not find evidence for a better or worse response to GnRH agonists in men with prostate cancer who were also on drugs for hypertension, dyslipidaemia, or hyperglycaemia.
Ämnesord
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi och kardiovaskulära sjukdomar (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiology and Cardiovascular Disease (hsv//eng)